Trial reportCancer science2018
Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
Trial report in Cancer science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 4 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review.Frontiers in pharmacology · 2023Pooled it
- The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China.Frontiers in pharmacology · 2022Pooled it
- The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: A PRISMA-compliant systematic review and meta-analysis.Medicine · 2020Pooled it
- Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis.Medicine · 2019Pooled it
- High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.Cell reports. Medicine · 2026Trial
- Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study.Journal of cancer research and clinical oncology · 2023Trial
- Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan.Japanese journal of clinical oncology · 2020Trial
- Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.Cancer science · 2018Trial
- Osimertinib for Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Current Evidence.Clinical Medicine Insights. Oncology · 2026Review
- Epidermal growth factor receptor inhibitor-related skin toxicities: a review of management and possible preventive and therapeutic approaches for Asian patients by the Japanese Pharmacist-led Oncodermatology Study Team.International journal of clinical oncology · 2025Review
- Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system.BMC cancer · 2025Article
- Serum creatine kinase elevation following tyrosine kinase inhibitor treatment in cancer patients: Symptoms, mechanism, and clinical management.Clinical and translational science · 2024Review
- Article
- Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis.Respiratory medicine case reports · 2024Article
- Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non-Small Cell Lung Cancer: Updated Analysis of the RESET Study.Cancer research and treatment · 2023Article
- Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.Cell communication and signaling : CCS · 2023Review
- Rhabdomyolysis in a patient with advanced lung cancer treated with osimertinib: a case report.Translational lung cancer research · 2023Article
- Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma.PloS one · 2023Article
- Significance of thyroid transcription factor 1 and Napsin A for prompting the status ofJournal of thoracic disease · 2022Article
- The predictive value ofTranslational cancer research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 10 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the first-line treatment for patients with EGFR mutant non-small-cell lung cancer (NSCLC). However, most patients become resistant to these drugs, so their disease progresses. Osimertinib, a third-generation EGFR-TKI that can inhibit the kinase even when the common resistance-conferring Thr790Met (T790M) mutation is present, is a promising therapeutic option for patients whose disease has progressed after first-line EGFR-TKI treatment. AURA3 was a randomized (2:1), open-label, phase III study comparing the efficacy of osimertinib (80 mg/d) with platinum-based therapy plus pemetrexed (500 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.